Biologic interventions in rheumatoid arthritis.
An increasing understanding of the immunopathogenesis of rheumatoid arthritis and advances in biotechnology have lead to the therapeutic application of immune-specific interventions. The complexity of this disorder has generated numerous investigations using a wide range of biologic interventions. This article presents the current and potential targets for such biopharmaceutical agents and discusses their utility in rheumatoid arthritis.
Cush
J J
JJ
University of Texas Southwestern Medical Center, Rheumatic Diseases Division, Dallas 75235-8577, USA.
Kavanaugh
A F
AF
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000906:Antibodies / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000628:therapy*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D016207:Cytokines / Q000502:physiology; D006681:HLA-D Antigens / Q000276:immunology; D006801:Humans; D016028:Receptors, Leukocyte-Adhesion / Q000187:drug effects
D000276:Adjuvants, Immunologic; D000906:Antibodies; D000911:Antibodies, Monoclonal; D016207:Cytokines; D006681:HLA-D Antigens; D016028:Receptors, Leukocyte-Adhesion